logo
Wrong email address or username
Wrong email address or username
Incorrect verification code
back to top
Search tags: cancer
Load new posts () and activity
Like Reblog Comment
text 2019-01-10 08:20
Serum Cancer Biomarkers Market

Serum biomarkers are proteins generally detected in urine, blood, and other bodily fluids produced by malignant cells or in reaction to presence/absence of malignant cells. Preferably, biomarkers should have at least one or more than one of the following properties: prompt detection of cancer within high risk population, diagnosis of specific type of cancer, prediction in its growth, screen its treatment response, and detect early recurrence.
The global serum cancer biomarkers market is projected to grow at a rapid pace in the next few years. Key drivers of the market are increase in the number of people suffering from different types of cancer and rise in the geriatric population. Increase in the cancerafflicted population is anticipated to be another key driver of the market.
The global Serum Cancer Biomarkers market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 20192025. The objectives of this study are to define, segment, and project the size of the Serum Cancer Biomarkers market based on company, product type, end user and key regions.

This report studies the global market size of Serum Cancer Biomarkers in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Serum Cancer Biomarkers in these regions.
This research report categorizes the global Serum Cancer Biomarkers market by top players/brands, region, type and end user. This report also studies the global Serum Cancer Biomarkers market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Roche
Pfizer
Novartis
Abbott
BD
Merck
Eli Lilly
Agilent Technologies
Boehringer Ingelheim
AstraZeneca
BristolMyers Squibb
Novo Nordisk
Allergan
Gilead

Market size by Product
Hepatocellular Carcinoma Serum Biomarkers
Lung Cancer Serum Biomarkers
Pancreatic & Biliary Tract Cancer Serum Biomarkers
Breast Cancer Serum Biomarkers
Glioblastoma Serum Biomarkers
Others
Market size by End User
Hospitals
Academic & Research Institutes
Ambulatory Surgical Centers
Others

Market size by Region
North America
United States
Canada
Mexico
AsiaPacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Serum Cancer Biomarkers market size value & volume by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Serum Cancer Biomarkers market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market growth potential, opportunities, drivers, industryspecific challenges and risks.
Focuses on the key global Serum Cancer Biomarkers companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Serum Cancer Biomarkers submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Serum Cancer Biomarkers are as follows:
History Year: 20142018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value million US$ and volume K Units. Both topdown and bottomup approaches have been used to estimate and validate the market size of Serum Cancer Biomarkers market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Source: www.qandqmarketresearch.com
Like Reblog Comment
text 2018-12-31 10:58
Colon and Rectal Cancer Drugs Market Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Colon and rectal cancer are often grouped together, as they have many common features. Rate of colorectal cancer is increasing among the millennials in the U.S. The American Cancer Society (ACS) estimates that there will be around 97,220 new cases of colon cancer and around 43,030 new cases of rectal cancer registered in the U.S. in 2018. Moreover, owing to increasing risk of colorectal cancer, in May 2018, ACS updated their guidelines for colorectal cancer screenings and recommended to start colorectal cancer screening at the age of 45 rather than at the age of 50.




Colon and Rectal Cancer Drugs Market – Drivers


Increasing incidence and prevalence of colon and rectal cancer, worldwide and increasing research and development studies for colorectal cancer treatment is expected to drive growth of colon and rectal cancer market in the near future. For instance, according to February 2018 data findings of the American Cancer Society (ACS), colorectal cancer is the third most common cancer diagnosed in both men and women in the U.S.


Download PDF Brochure of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-pdf/2019

 

Moreover, according to the Center for Disease Control and Prevention (CDC), in 2014, around 139,992 people in the U.S. were diagnosed with colorectal cancer, including 73,396 men and 66,596 women. Among which, around 51,651 people in the U.S. died due to colorectal cancer, including 27,134 men and 24,517 women. Furthermore, according to 2012 data findings of the World Health Organization (WHO), colorectal cancer is the third most common cancer in men (746,000 cases, 10.0% of the total) and the second most common in women (614,000 cases, 9.2% of the total) worldwide, in 2012. Furthermore, around 55% of these cases occurred in developed regions.   


Increasing number of research and development (R&D) studies by government and private healthcare organizations is also fueling growth of colon and rectal cancer drugs market. For instance, the American Cancer Society (ACS) spend US$ 54 million on colon and rectal cancer research involving 92 research grants, till March 2018.       


Colon and Rectal Cancer Drugs Market – Regional Analysis


On the basis of region, the global colon and rectal cancer drugs market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds dominant position in the colon and rectal cancer drugs market, followed by Europe. This is owing to increasing incidence rate of colorectal cancer in these regions. According to the World Cancer Research Fund International, in 2012, Republic of Korea had the highest rate of colorectal cancer, followed by Slovakia and Hungary. Furthermore, since few years, large number of colorectal cancer incidences were registered in Oceania and Europe region, while it shows lowest incidence rates in Africa and Asia region.


Colon and Rectal Cancer Drugs Market – Competitive Analysis


Some of the key players operating in the global colon and rectal cancer drugs market include Amgen Inc., AstraZeneca plc, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo Company, Merck KGaA, Novartis International AG, Sirtex Medical Limited, Sanofi S.A. Sorrento Therapeutics, and Takeda Pharmaceutical Company Ltd. Key players in the market are involved in research and development activities to conduct clinical trial studies and to gain regulatory approval. For instance, in March 2018, Daiichi Sankyo initiated phase II study of DS-8201 in patients with HER2-expressing advanced colorectal cancer. Currently, there is no HER2 –targeting therapy approved for patients suffering from HER2- expressing colorectal cancer. Initiation of HER2 phase clinical trial study by Daiichi Sankyo for colorectal cancer treatment will help to improve the outcomes in colorectal cancer patients. In March 2018, FDA approved Bristol-Myers Squibb’s Opdivo (nivolumab) injection, which is administrated intravenously for the treatment of adult and pediatric (12 years and older) patients who suffer from microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer.


Request For Customization Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-customization/2019


Colon and Rectal Cancer Drugs Market – Taxonomy


The global colon and rectal cancer drugs market is segmented on the basis of drug type, distribution channel, and region as mentioned below:  

By Drug Type:

  • Single Drug

    • Colon Cancer

      • Cetuximab

      • Bevacizumab

      • Avastin

      • Capecitabine

      • Nivolumab

      • Panitumumab

      • Oxaliplatin

      • Others

    • Rectal Cancer

      • Avastin

      • Capecitabine

      • Erbitux

      • Cyramza

      • Irinotecan Hydrochloride

      • Nivolumab

      • Others

    • Combination Drug

      • Colon Cancer

        • CAPOX

        • FOLFOX

        • FOLFIRI

        • FOLFIRI-CETUXIMAB

        • XELIRI

        • Others

      • Rectal Cancer

        • FU-LV

        • CAPOX

        • FOLFIRI-BEVACIZUMAB

        • XELOX

        • XELIRI

        • Others

By Distribution Channels:

  • Hospitals Pharmacies

  • Retail Pharmacies

  • Online Pharmacies


Colon and Rectal Cancer Drugs Market – Restraints


Lack of development in the neoadjuvant/adjuvant pipeline agents for the treatment of high risk colorectal cancer resulted in slower growth of colon and rectal cancer drugs market. For instance, according to the data published in the National Center for Biotechnology Information (NCBI) in April 2016, there is lack of clinical trials of systemic adjuvant, neoadjuvant, and perioperative chemotherapy for the treatment of colorectal liver metastases (CRLM). These offers lucrative opportunity for the key players to develop new treatment therapy using neoadjuvant agents for resected patients.  


About Coherent Market Insights:


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.



Contact Us:


Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com



Like Reblog Comment
show activity (+)
review 2018-12-30 23:38
THE DEAL OF A LIFETIME by Fredrik Backman
The Deal of a Lifetime: A Novella - Fredrik Backman
A man is in the hospital with cancer.  He meets a 5-year-old who also has cancer.  He notices an emissary of the Grim Reaper hanging around.  He reflects on his past.  He also confronts the emissary who denies she has come for him.  He realizes who she is after and offers to take the child's place but the emissary is not there for a death for a death but rather a life for a life. 
 
This is an odd book.  It's short and a quick read but makes you question how far would you go for someone else?  I like the explanation she gives about the difference between a death for a death and a life for a life.  I think about this at odd times.  How far would I go?
Like Reblog Comment
show activity (+)
review 2018-12-29 19:46
The light in the darkness
The Bright Hour - Nina Riggs Jones

Well, here I am talking about cancer and dying again. I swear it's the last of these for a good long while, guys. (I hope I don't end up eating my words.) The Bright Hour: A Memoir of Living and Dying by Nina Riggs was recommended to me after reading When Breath Becomes Air because Nina's widowed husband is now dating the widow of Paul Kalinithi who wrote the aforementioned. O_O  At the start of her story, Nina was 38 years old and her biggest problems centered around publishing her newest bit of writing and mothering her two young sons with her husband...and then Cancer rapidly derailed her life. When Nina was initially diagnosed with breast cancer her mother was fighting her own battle with an aggressive myeloma. At first, Nina's diagnosis seemed quite straightforward in comparison. Her doctor felt it was quite treatable with a mastectomy and chemo but right as her life seemed to stabilize a stabbing back pain (reminiscent of Paul Kalinithi) made itself known. This turned out to be the harbinger of Stage 4 cancer which unfortunately was not curable. To add insult to injury, her mother's cancer stopped responding to treatment and she opted to stop her treatment. Overwhelming and almost unbelievably melodramatic as this all sounds Nina chose to view each day through a positive lens. It is obvious to me that she was a special person with a whole lot of spirit. Sadly, she passed away before final publication of her book but her legacy still lives and breathes on each page of her memoir. I'm sorry we can't enjoy more writing from her in the future.  9/10

 

What's Up Next: The Science of Supervillains by Lois H. Gresh & Robert Weinberg

 

What I'm Currently Reading: Tales from the Inner City by Shaun Tan

Source: readingfortheheckofit.blogspot.com
Like Reblog Comment
text 2018-12-26 09:00
Bile Duct Cancer Market

Bile duct cancer or cholangiocarcinoma is a form of cancer in which epithelial cells are mutated, i.e., they show epithelial differentiation in the bile duct. It is a type of rare neoplasm.
The global Bile Duct Cancer market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 20192025. The objectives of this study are to define, segment, and project the size of the Bile Duct Cancer market based on company, product type, end user and key regions.

This report studies the global market size of Bile Duct Cancer in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Bile Duct Cancer in these regions.
This research report categorizes the global Bile Duct Cancer market by top players/brands, region, type and end user. This report also studies the global Bile Duct Cancer market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Pfizer
F. HoffmannLa Roche
BristolMyers Squibb
Teva Pharmaceutical
Eli Lilly and Company
Sanofi
Fresenius Kabi
Mylan

Market size by Product
5fluorouracil
Gemcitabine
Cisplatin
Other
Market size by End User
Hospitals & Clinics
Other

Market size by Region
North America
United States
Canada
Mexico
AsiaPacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Bile Duct Cancer market size value & volume by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Bile Duct Cancer market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market growth potential, opportunities, drivers, industryspecific challenges and risks.
Focuses on the key global Bile Duct Cancer companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Bile Duct Cancer submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Bile Duct Cancer are as follows:
History Year: 20142018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value million US$ and volume K Units. Both topdown and bottomup approaches have been used to estimate and validate the market size of Bile Duct Cancer market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Source: www.qandqmarketresearch.com
More posts
Your Dashboard view:
Need help?